Skip to content

Study · Not a test of the peptide alone · 2015

6 results

Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience.

Fujioka K, Sparre T, Sun LY, Krogsgaard S, Kushner RF

Journal of diabetes science and technology16 Jul 2015Cited by 7 (Europe PMC)

PMID26183599 (opens in a new tab)PMCIDPMC4738203 (opens in a new tab)DOI10.1177/1932296815593295 (opens in a new tab)PepBankPUB-26183599
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneOther designSafety outcome

    In overweight or obese adults, the liraglutide 3.0 mg pen injector usability test found no potentially serious use errors and low numbers of nonserious errors.

    In plain wordsIn a usability test, people using the liraglutide 3.0 mg pen made no potentially serious use errors.

    Peptide
    Liraglutide
    Outcome
    No significant changePotentially serious use errors
    Study

    n = 234

    Outcome group
    Device usability · Whole body

    Source sentences

    Summary
    No potentially serious use errors, and low numbers of nonserious errors, were reported.
    1 context sentence
    Summary · context
    The current analysis used a summative usability test to assess safety and effectiveness, ease of use, and training requirements for the novel liraglutide 3.0 mg pen injector.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneOther designSafety outcome

    In the usability test of the liraglutide 3.0 mg pen injector, participants committed 105 use errors related to handling, with no potential for harm.

    In plain wordsIn a usability test of the liraglutide pen, participants made 105 handling errors, none with potential for harm.

    Peptide
    Liraglutide
    Outcome
    Not applicableNonserious use errors related to handling
    Study

    n = 234

    Outcome group
    Device usability · Whole body

    Measurements

    use errors
    105 errors
    all participants

    Source sentences

    Summary
    Overall, participants committed 105 use errors related to handling, with no potential for harm.
    1 context sentence
    Summary · context
    The current analysis used a summative usability test to assess safety and effectiveness, ease of use, and training requirements for the novel liraglutide 3.0 mg pen injector.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneOther designSafety outcome

    In the usability test of the liraglutide 3.0 mg pen injector, 25 close calls and 44 operational difficulties were reported without a pattern that showed a design flaw.

    In plain wordsIn a usability test of the liraglutide pen, 25 close calls and 44 operational difficulties occurred, with no pattern pointing to a design flaw.

    Peptide
    Liraglutide
    Outcome
    Not applicableClose calls and operational difficulties
    Study

    n = 234

    Outcome group
    Device usability · Whole body

    Measurements

    close calls
    25 events
    all participants
    operational difficulties
    44 events
    all participants

    Source sentences

    Summary
    A total of 25 close calls and 44 operational difficulties were reported without any pattern indicative of a design flaw.
    1 context sentence
    Summary · context
    The current analysis used a summative usability test to assess safety and effectiveness, ease of use, and training requirements for the novel liraglutide 3.0 mg pen injector.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneOther designOther

    In the usability test of the liraglutide 3.0 mg pen injector, the incidence of events differed markedly between trained and untrained participants, regardless of prior injection experience.

    In plain wordsIn a usability test of the liraglutide pen, trained and untrained participants had clearly different numbers of events.

    Peptide
    Liraglutide
    Outcome
    MixedUse errors in trained versus untrained participants
    Study

    n = 234

    Outcome group
    Device usability · Whole body

    Source sentences

    Summary
    Marked differences in the incidence of events were observed for trained versus untrained participants regardless of prior injection experience.
    1 context sentence
    Summary · context
    The current analysis used a summative usability test to assess safety and effectiveness, ease of use, and training requirements for the novel liraglutide 3.0 mg pen injector.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05HumanNot a test of Liraglutide aloneOther designOther

    In the usability test of the liraglutide 3.0 mg pen injector, participants rated ease of use as 6.4 on a 7-point scale.

    In plain wordsIn a usability test of the liraglutide pen, participants rated ease of use as 6.4 out of 7.

    Peptide
    Liraglutide
    Outcome
    Not applicableEase of use rating
    Study

    n = 234

    Outcome group
    Device usability · Whole body

    Measurements

    ease of use rating
    6.4 points of 7
    participants

    Source sentences

    Summary
    Participants rated ease of use as 6.4/7.
    1 context sentence
    Summary · context
    The current analysis used a summative usability test to assess safety and effectiveness, ease of use, and training requirements for the novel liraglutide 3.0 mg pen injector.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 06HumanNot a test of Liraglutide aloneOther designSafety outcome

    In the usability test of the liraglutide 3.0 mg pen injector, all assessed participants interpreted the instructions for use correctly.

    In plain wordsIn a usability test of the liraglutide pen, all assessed participants understood the instructions correctly.

    Peptide
    Liraglutide
    Outcome
    Not applicableCorrect interpretation of instructions for use
    Study

    n: not reported in source

    Outcome group
    Device usability · Whole body

    Source sentences

    Summary
    All assessed participants interpreted the instructions for use correctly.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.